Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system

被引:9
|
作者
Zhang, Ying [1 ]
Ran, Li [1 ]
Liang, Yongchao [1 ]
Zhang, Yanqiu [1 ]
An, Zhuoling [1 ]
机构
[1] Capital Med Univ, Beijing Chao Yang Hosp, Dept Pharm, Beijing, Peoples R China
关键词
pemigatinib; Food and Drug Administration adverse event reporting system; disproportionality analysis; real-word study; Advers drug events; PHASE-II; METASTATIC CHOLANGIOCARCINOMA; PATIENTS PTS; OPEN-LABEL; IN-VIVO; HYPOPHOSPHATEMIA; MULTICENTER; EXPRESSION; INHIBITORS; BGJ398;
D O I
10.3389/fphar.2023.1194545
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Cholangiocarcinoma (CCA) is a highly lethal and aggressive epithelial tumor of the hepatobiliary system. A poor prognosis, propensity for relapse, low chance of cure and survival are some of its hallmarks. Pemigatinib, the first targeted treatment for CCA in the United States, has been demonstrated to have a significant response rate and encouraging survival data in early-phase trials. The adverse events (AEs) of pemigatinib must also be determined.Objective: To understand more deeply the safety of pemigatinib in the real world through data-mining of the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).Methods: Disproportionality analysis was employed in a retrospective pharmacovigilance investigation to identify the AEs linked to pemigatinib use as signals. Data were collected between 1 January 2020 to 30 June 2022. Four data-mining methods (proportional reporting odds ratio; proportional reporting ratio; Bayesian confidence propagation neural networks of information components; empirical Bayes geometric means) were used to calculate disproportionality.Results: A total of 203 cases using pemigatinib as the prime-suspect medication were found in our search, which involved 99 preferred terms (PTs). Thirteen signals of pemigatinib-induced AEs in seven System Organ Classes were detected after confirming the four algorithms simultaneously. Nephrolithiasis was an unexpected significant AE not listed on the drug label found in our data-mining. Comparison of the differences between pemigatinib and platinum drugs in terms of 33 PTs revealed that 13 PTs also met the criteria of the four algorithms. Ten of these PTs were identical to those compared with all other drugs, in which (excluding a reduction in phosphorus in blood) other PT signal values were higher than those of all other drugs tested. However, comparison of the differences between pemigatinib and infigratinib in terms of the 33 PTs revealed no significant signals in each algorithm method.Conclusion: Some significant signals were detected between pemigatinib use and AEs. PTs with apparently strong signals and PTs not mentioned in the label should be taken seriously.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database
    Subeesh, Viswam
    Maheswari, Eswaran
    Singh, Hemendra
    Beulah, Thomas Elsa
    Swaroop, Ann Mary
    CURRENT DRUG SAFETY, 2019, 14 (01) : 21 - 26
  • [22] Performance of subgrouped proportional reporting ratios in the US food and drug administration (FDA) adverse event reporting system
    Dauner, Dan
    Zhang, Rui
    Adam, Terrence
    Leal, Eleazar
    Farley, Joel F.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 598 - 598
  • [23] Empirical estimation of under-reporting in the US Food and Drug Administration Adverse Event Reporting System (FAERS)
    Alatawi, Yasser M.
    Hansen, Richard A.
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (07) : 761 - 767
  • [24] Performance of subgrouped proportional reporting ratios in the US Food and Drug Administration (FDA) adverse event reporting system
    Dauner, Daniel G.
    Zhang, Rui
    Adam, Terrence J.
    Leal, Eleazar
    Heitlage, Viviene
    Farley, Joel F.
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (07) : 589 - 597
  • [25] Comparisons of adverse event reporting for colistin versus polymyxin B using the US Food and Drug Administration Adverse Event Reporting System (FAERS)
    Cong Bang Truong
    Durham, Spencer H.
    Qian, Jingjing
    EXPERT OPINION ON DRUG SAFETY, 2021, 20 (05) : 603 - 609
  • [26] Mortality and adverse events with brand and generic clopidogrel in the US Food and Drug Administration Adverse Event Reporting System
    Serebruany, Victor L.
    Hall, Trygve S.
    Atar, Dan
    Agewall, Stefan
    Kim, Moo Hyun
    Geudelin, Bernard
    Lomakin, Nikita
    Marciniak, Thomas A.
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2019, 5 (04) : 210 - 215
  • [27] An Ecological Study on Consumer Adverse Event Reporting to the US Food and Drug Administration
    Munoz, M.
    Dal Pan, G.
    Xiao, H.
    Delcher, C.
    Wei, J.
    Kortepeter, C.
    Winterstein, A.
    DRUG SAFETY, 2018, 41 (11) : 1132 - 1132
  • [28] Adverse Event Profile of Tigecycline: Data Mining of the Public Version of the US Food and Drug Administration Adverse Event Reporting System
    Kadoyama, Kaori
    Sakaeda, Toshiyuki
    Tamon, Akiko
    Okuno, Yasushi
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2012, 35 (06) : 967 - 970
  • [29] Data mining and safety analysis of avatrombopag: a retrospective pharmacovigilance study based on the US food and drug administration's adverse event reporting system
    Zhu, Hong
    Wu, Meng
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [30] Intestinal Adverse Outcomes With Pancreatic Enzymes: An Analysis of the Food and Drug Administration Adverse Event Reporting System
    Stobaugh, Derrick J.
    Deepak, Parakkal
    Ehrenpreis, Eli D.
    GASTROENTEROLOGY, 2013, 144 (05) : S457 - S457